|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
bThe use of the skin as an alternative route of delivering medicaments has been the subject of intense research over the past 25 years, however its growth has been slow until recently.
The market for transdermal devices is currently estimated at US billion (1), which represents 10 per cent of the entire US billion drug delivery market. In addition, transdermal drug delivery has recently experienced a healthy annual growth rate of 25 per cent, which outpaces oral drug delivery (two per cent) and the inhalation market (20 per cent) (2). Such growth is astonishing when it is considered that the worldwide transdermal therapy market is currently based on only 10 drugs, in spite of the fact that the first transdermal patch was approved by the FDA in 1979. This short list of 'deliverables' highlights the physicochemical restrictions imposed on drug delivery across the skin.
The barrier nature of human skin as a result of its protective function imposes physicochemical limitations to the type of permeant that can traverse the barrier. For a drug to be delivered passively via the skin, it needs to have adequate lipophilicity (Log P, octanol/water 1-3) and also a molecular weight <500Da. A review of patent databases at the United States Patent Office shows that prior to 1980 only six patents had been issued which contained the word OtransdermalO within the patent specifications or claims. As of February 2001, this figure had grown to well over a thousand (3). Thus, with the possible emergence of efficacious and portable, operator friendly, safe, cost-effective devices which circumvent the skin barrier, the addition of new drugs and biopharmaceuticals to currently marketed products will inevitably add value to transdermal drug delivery. This review provides an overview of some of the devices currently in development. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Line Clearance in Pharmaceutical Packaging & Manufacturing
5 February 2009, Manchester, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
|
